Voronoi Merges Three Companies to 'Maximize Research Efficiency'
2023.03.08
⚫ Voronoi Inc. to absorb subsidiaries B2S Bio and Voronoi Bio through merger
⚫ CEO Daekwon Kim: "We will do our utmost in pipeline discovery and license-out deals"
Voronoi Inc. (CEOs Daekwon Kim and Hyuntae Kim), a global drug design company, plans to maximize R&D efficiency through the merger of its subsidiaries.
Voronoi announced that at a board meeting on the 8th it resolved to merge its unlisted subsidiaries B2S Bio and Voronoi Bio into the parent company, KOSDAQ-listed Voronoi. The Voronoi group, which has built a track record of approximately USD 2.3 billion (KRW 2.9 trillion) through five global license-out deals since 2020, expects this integration to enable faster decision-making and improved R&D efficiency.
The company noted that until now, artificial intelligence (AI) modeling and cell and animal studies (in vitro, in vivo) had been handled by the parent company while medicinal synthesis was handled by a subsidiary, but this merger will achieve complete integration of the R&D process and maximize efficiency. The company also stated that the integration will enable faster decision-making on matters such as target selection in early discovery research, thereby accelerating the discovery of pipeline programs in areas with promising market potential.
CEO Daekwon Kim of Voronoi Inc., which will continue as the single surviving company after the merger, said, "As the three-way merger further strengthens our R&D capabilities, our 120 employees will do their utmost to achieve rapid success in pipeline discovery, license-out deals, and clinical research."
⚫ CEO Daekwon Kim: "We will do our utmost in pipeline discovery and license-out deals"
Voronoi Inc. (CEOs Daekwon Kim and Hyuntae Kim), a global drug design company, plans to maximize R&D efficiency through the merger of its subsidiaries.
Voronoi announced that at a board meeting on the 8th it resolved to merge its unlisted subsidiaries B2S Bio and Voronoi Bio into the parent company, KOSDAQ-listed Voronoi. The Voronoi group, which has built a track record of approximately USD 2.3 billion (KRW 2.9 trillion) through five global license-out deals since 2020, expects this integration to enable faster decision-making and improved R&D efficiency.
The company noted that until now, artificial intelligence (AI) modeling and cell and animal studies (in vitro, in vivo) had been handled by the parent company while medicinal synthesis was handled by a subsidiary, but this merger will achieve complete integration of the R&D process and maximize efficiency. The company also stated that the integration will enable faster decision-making on matters such as target selection in early discovery research, thereby accelerating the discovery of pipeline programs in areas with promising market potential.
CEO Daekwon Kim of Voronoi Inc., which will continue as the single surviving company after the merger, said, "As the three-way merger further strengthens our R&D capabilities, our 120 employees will do their utmost to achieve rapid success in pipeline discovery, license-out deals, and clinical research."